Results 281 to 290 of about 276,897 (341)
Unveiling the interplay between microbiota and PD1/PD-L1 axis in tumor immunity and immunotherapy. [PDF]
Lu Q, Wu J, Yu X, Qian J, Song Z.
europepmc +1 more source
PD-L1 Expression in Pancreatic Cancer [PDF]
openaire +2 more sources
This study designed a tumor microenvironment‐responsive AIEgen nanoparticle for near‐infrared photoimmunotherapy, which inhibits primary tumors and metastasis by promoting pyroptosis and suppressing aerobic glycolysis. ABSTRACT In advanced osteosarcoma, tumor invasion often prevents complete resection, and immunotherapy is limited by the tumor's ...
Kaiyuan Liu +14 more
wiley +1 more source
Anti-PD-1/PD-L1 Immunotherapy as a Potential Treatment Option for Lung Cancer: A Perspective Analysis of Opportunities and Challenges. [PDF]
Mohiuddin M.
europepmc +1 more source
USP35 Acts as a Deubiquitinating Enzyme for ID3 to Promote Immune Escape in Colorectal Cancer
USP35 stabilizes ID3 expression by deubiquitinating the K2/K30 site, thereby upregulating PD‐L1 and promoting immune escape in colorectal cancer. IU1, an inhibitor of USP35 enzyme activity, has been shown to inhibit USP35, thereby accelerating ID3 degradation, enhancing CD8+ T cell killing, and reversing the immunosuppressive microenvironment ...
Wenxin Chen +9 more
wiley +1 more source
IL27RA upregulation drives immune evasion in TNBC by suppressing MHC‐I expression and reprogramming T/NK‐cell states, establishing an immune‐excluded tumor phenotype. Targeting this epithelial‐intrinsic IL27RA–PI3K/AKT axis offers a promising strategy to overcome immunotherapy resistance.
Jiachi Xu +8 more
wiley +1 more source

